Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
8-KReport of unscheduled material events or corporate eventMay 5, 2004View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionMay 5, 2004View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventApr 22, 2004View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventApr 22, 2004View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesApr 5, 2004View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesApr 2, 2004View HTMLDownload DOCDownload PDF
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 1, 2004View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formMar 19, 2004View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formMar 11, 2004View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formMar 4, 2004View HTMLDownload DOCDownload PDFDownload XLS
POS AMPost-effective amendment to an S-Type filingMar 3, 2004View HTMLDownload DOCDownload PDFDownload XLS
10-KAnnual report which provides a comprehensive overview of the company for the past yearFeb 27, 2004View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventFeb 24, 2004View HTMLDownload DOCDownload PDFDownload XLS
POS AMPost-effective amendment to an S-Type filingFeb 24, 2004View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 17, 2004View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 12, 2004View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventFeb 4, 2004View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formFeb 4, 2004View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventFeb 3, 2004View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 3, 2004View HTMLDownload DOCDownload PDF
3Initial filing by director officer or owner of more than ten percent.Jan 27, 2004View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 27, 2004View HTMLDownload DOCDownload PDF
3Initial filing by director officer or owner of more than ten percent.Jan 2, 2004View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 2, 2004View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 2, 2004View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-78

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information